This multicenter, double-blind, placebo-controlled trial evaluated the efficacy of anthocyanin-rich extract (ACRE), derived from bilberries, in patients with moderate-to-severe ulcerative colitis (UC). Although the study was prematurely terminated due to COVID-19, 34 patients were randomized, and 26 completed the protocol. Clinical response was observed in 50% of ACRE-treated patients versus 37.5% in the placebo group. While superiority was not statistically significant, ACRE led to meaningful reductions in fecal calprotectin (p = 0.035), indicating anti-inflammatory activity. Mayo scores improved in 77.8% of ACRE patients compared to 62.5% with placebo. ACRE was generally well tolerated, highlighting its potential as a supportive therapy for UC.
